Volitionrx (VNRX) Net Income towards Common Stockholders (2012 - 2025)
Volitionrx (VNRX) posted Net Income towards Common Stockholders of $260595.0 for Q4 2025, up 929.05% on a QoQ basis from -$31433.0 in Q3 2025, and up 104.5% year-over-year from $127431.5 in Q4 2024.
Volitionrx (VNRX) Net Income towards Common Stockholders (2012 - 2025) Analysis & Trends
Volitionrx's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at $260595.0 for Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 104.5% year-over-year to $260595.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$5.7 million (up 78.95% YoY) and the FY2025 annual result came in at $146302.0, up 100.54% from the prior year.
- Net Income towards Common Stockholders was $260595.0 for Q4 2025 at Volitionrx, up from -$31433.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $260595.0 in Q4 2025 and bottomed at -$9.5 million in Q2 2023.
- A 5-year average of -$4.9 million and a median of -$6.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders tumbled 88751.34% — and 2022, when it surged 791.1%.
- Volitionrx's Net Income towards Common Stockholders stood at -$8.0 million in 2021, then climbed by 9.87% to -$7.2 million in 2022, then decreased by 20.11% to -$8.7 million in 2023, then soared by 33.4% to -$5.8 million in 2024, then surged by 104.5% to $260595.0 in 2025.
- Business Quant data shows VNRX's Net Income towards Common Stockholders at $260595.0 in Q4 2025, -$31433.0 in Q3 2025, and $29992.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.58 Bn | 176.28 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 129.01 Bn | 126.13 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.67 Bn | 67.22 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.33 Bn | 44.66 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.34 Bn | 27.23 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 28.07 Bn | 25.79 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.12 Bn | 21.00 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Volitionrx | 88,730.44 | -1.03 Mn | - | 260,595.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 260,595.00 |
| Sep 30, 2025 | -31,433.00 |
| Jun 30, 2025 | 29,992.00 |
| Mar 31, 2025 | -5.94 Mn |
| Dec 31, 2024 | -5.79 Mn |
| Sep 30, 2024 | -5.82 Mn |
| Jun 30, 2024 | -6.99 Mn |
| Mar 31, 2024 | -8.37 Mn |
| Dec 31, 2023 | -8.70 Mn |
| Sep 30, 2023 | -8.37 Mn |
| Jun 30, 2023 | -9.47 Mn |
| Mar 31, 2023 | -8.78 Mn |
| Dec 31, 2022 | -7.24 Mn |
| Sep 30, 2022 | -7.74 Mn |
| Jun 30, 2022 | 82,302.00 |
| Mar 31, 2022 | 83,977.00 |
| Dec 31, 2021 | -8.04 Mn |
| Sep 30, 2021 | -7.14 Mn |
| Jun 30, 2021 | 47,539.00 |
| Mar 31, 2021 | 9,424.00 |